Table 4.

Clinical trials of combination therapies for CRPCa with taxanes

Clinical Trial	Primary Anti-Cancer Agent	Secondary Anticancer Agent	Phase	N	Primary Outcome	Result	Reference
SYNERGY (NCT01188187)	Docetaxel	Custirsen	III	1022	Overall Survival	No Survival Benefit	Chi et al. 2017 [102]
READY (NCT00744497)	Docetaxel	Dastinib (Src Inhibitor)	III	1522	Overall Survival	No Survival Benefit	Araujo et al. 2013 [99]
TRAPEZE (NCT00554918)	Docetaxel	Strontium-89 or Zolendronic Acid (Osteoclast Inhibitor)	II	757	PFS and Cost-Efficacy	St-89 improved PFS, ZA Reduced Bone Metastasis, No Survival Benefit	James et al. 2016 [101]

Several other combinations with docetaxel have been analyzed for their efficacy against CRPC. However, docetaxel continues to have associated toxicities that result in reduced survival or lower the quality of life.